MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Avita Therapeutics Inc

Geschlossen

4.14 7.25

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.7800000000000002

Max

4.18

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.3M

-13M

Verkäufe

-1.4M

17M

Gewinnspanne

-77.289

Angestellte

260

EBITDA

-3.2M

-11M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.36% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.1M

119M

Vorheriger Eröffnungskurs

-3.11

Vorheriger Schlusskurs

4.14

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Avita Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Jan. 2026, 21:55 UTC

Ergebnisse

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22. Jan. 2026, 23:52 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22. Jan. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22. Jan. 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22. Jan. 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Jan. 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22. Jan. 2026, 22:37 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22. Jan. 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

22. Jan. 2026, 21:44 UTC

Ergebnisse

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22. Jan. 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22. Jan. 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22. Jan. 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22. Jan. 2026, 21:30 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One To Acquire Brex >COF

22. Jan. 2026, 21:13 UTC

Ergebnisse

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22. Jan. 2026, 21:11 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22. Jan. 2026, 21:11 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22. Jan. 2026, 21:10 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22. Jan. 2026, 21:06 UTC

Ergebnisse

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Rev $15.58B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q EPS $3.26 >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net Interest Margin 8.26% >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net $2.13B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Adj EPS $3.86 >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net Charge-Offs $3.8B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Intuitive Surgical 4Q EPS $2.21 >ISRG

Peer-Vergleich

Kursveränderung

Avita Therapeutics Inc Prognose

Kursziel

By TipRanks

19.36% Vorteil

12-Monats-Prognose

Durchschnitt 4.5 USD  19.36%

Hoch 5.5 USD

Tief 3.5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Avita Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

1

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

8.83 / 9.77Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat